FDA approves label extension for Evrysdi for infants with spinal muscular atrophy under 2 months old

PTC Therapeutics

31 May 2022 - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date.

PTC Therapeutics today announced that the U.S. FDA has approved a label extension for Evrysdi (risdiplam) to include infants under 2 months old with spinal muscular atrophy.

Read PTC Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Paediatrics